Close Menu

Grail: Gautam Kollu

Grail has appointed Gautam Kollu as chief commercial officer. Kollu previously served as VP of global market development at Illumina. Before Illumina, Kollu served as VP of marketing, medical affairs, and business development at Natera. Prior to Natera, he served as VP of commercial at Exelixis and worked in several marketing and commercial roles at Genentech.


Seven Bridges: Michael Bigda 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.